dabigatran etexilate: package leaflet
For patients
Package leaflet, verbatim
Package leaflet: Pradaxa 75 mg hard capsules / dabigatran etexilate
1. What Pradaxa is and what it is used for
Pradaxa contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.
Pradaxa is used in adults to:
- prevent the formation of blood clots in the veins after knee or hip replacement surgery.
Pradaxa is used in children to:
- treat blood clots and to prevent blood clots from reoccurring.
2. What you need to know before you take Pradaxa
Do not take Pradaxa
- if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
- if you have severely reduced kidney function.
- if you are currently bleeding.
- if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
- if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
- if you are taking medicines to prevent blood clotting (e.g. warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open or while your heart beat is being restored to normal by a procedure called catheter ablation for atrial fibrillation.
- if you have a severely reduced liver function or liver disease which could possibly cause death.
- if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections.
- if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation.
- if you are taking dronedarone, a medicine used to treat abnormal heart beat.
- if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C
- if you have received an artificial heart valve which requires permanent blood thinning.
Warnings and precautions
Talk to your doctor before taking Pradaxa. You may also need to talk to your doctor during treatment with this medicine if you experience symptoms or if you have to undergo surgery.
Tell your doctor if you have or have had any medical conditions or illnesses, in particular any of those included in the following list:
- if you have an increased bleeding risk, such as:
▪ if you have been recently bleeding.
▪ if you have had a surgical tissue removal (biopsy) in the past month.
▪ if you have had a serious injury (e.g. a bone fracture, head injury or any injury requiring surgical treatment).
▪ if you are suffering from an inflammation of the gullet or stomach.
▪ if you have problems with reflux of gastric juice into the gullet.
▪ if you are receiving medicines which could increase the risk of bleeding. See ‘Other medicines and Pradaxa’ below.
▪ if you are taking anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam.
▪ if you are suffering from an infection of the heart (bacterial endocarditis).
▪ if you know you have decreased kidney function, or you are suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) / foaming urine).
▪ if you are older than 75 years.
▪ if you are an adult patient and weigh 50 kg or less.
▪ only if used for children: if the child has an infection around or within the brain.
- if you have had a heart attack or if you have been diagnosed with conditions that increase the risk to develop a heart attack.
- if you have a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.
Take special care with Pradaxa
- if you need to have an operation:
In this case Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
- if an operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
▪ it is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
▪ tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.
- if you fall or injure yourself during treatment, especially if you hit your head. Please seek urgent medical attention. You may need to be checked by a doctor, as you may be at increased risk of bleeding.
- if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.
Other medicines and Pradaxa
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular you should tell your doctor before taking Pradaxa, if you are taking one of the medicines listed below:
- Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid)
- Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin
- Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil).
If you are taking amiodarone, quinidine or verapamil containing medicines, your doctor may tell you to use a reduced dose of Pradaxa depending on the condition for which it is prescribed to you. See also section 3.
- Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine)
- A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C)
- Anti-inflammatory and pain reliever medicines (e.g. acetylsalicylic acid, ibuprofen, diclofenac)
- St. John´s wort, a herbal medicine for depression
- Antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin- norepinephrine re-uptake inhibitors
- Rifampicin or clarithromycin (two antibiotics)
- Anti-viral medicines for AIDS (e.g. ritonavir)
- Certain medicines for treatment of epilepsy (e.g. carbamazepine, phenytoin)
Pregnancy and breast-feeding
The effects of Pradaxa on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant unless your doctor advises you that it is safe to do so. If you are a woman of child-bearing age, you should avoid becoming pregnant while you are taking Pradaxa.
You should not breast-feed while you are taking Pradaxa.
Driving and using machines
Pradaxa has no known effects on the ability to drive or use machines.
3. How to take Pradaxa
Pradaxa capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. Pradaxa coated granules are available for the treatment of children below 12 years as soon as they are able to swallow soft food.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Take Pradaxa as recommended for the following conditions:
Prevention of blood clot formation after knee or hip replacement surgery
The recommended dose is 220 mg once a day (taken as 2 capsules of 110 mg).
If your kidney function is decreased by more than half or if you are 75 years of age or older, the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).
If you are taking amiodarone, quinidine or verapamil containing medicines the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).
If you are taking verapamil containing medicines and your kidney function is decreased by more than half, you should be treated with a reduced dose of 75 mg Pradaxa because your bleeding risk may be increased.
For both surgery types, treatment should not be started if there is bleeding from the site of operation. If the treatment cannot be started until the day after surgery, dosing should be started with 2 capsules once a day.
After knee replacement surgery
You should start treatment with Pradaxa within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 10 days.
After hip replacement surgery
You should start treatment with Pradaxa within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 28-35 days.
Treatment of blood clots and prevention of blood clots from reoccurring in children
Pradaxa should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.
The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose as treatment progresses. Keep using all other medicines, unless your doctor tells you to stop using any.
Table 1 shows single and total daily Pradaxa doses in milligrams (mg). The doses depend on weight in kilograms (kg) and age in years of the patient.
Table 1:
Dosing table for Pradaxa capsules
Weight / age combinations
Single dose in mg
Total daily dose in mg
Weight in kg
Age in years
11 to less than 13 kg
8 to less than 9 years
13 to less than 16 kg
8 to less than 11 years
16 to less than 21 kg
8 to less than 14 years
21 to less than 26 kg
8 to less than 16 years
26 to less than 31 kg
8 to less than 18 years
31 to less than 41 kg
8 to less than 18 years
41 to less than 51 kg
8 to less than 18 years
51 to less than 61 kg
8 to less than 18 years
61 to less than 71 kg
8 to less than 18 years
71 to less than 81 kg
8 to less than 18 years
81 kg or greater
10 to less than 18 years
Single doses requiring combinations of more than one capsule:
300 mg:
two 150 mg capsules or four 75 mg capsules
260 mg:
one 110 mg plus one 150 mg capsule or one 110 mg plus two 75 mg capsules
220 mg:
two 110 mg capsules
185 mg:
one 75 mg plus one 110 mg capsule
150 mg:
one 150 mg capsule or two 75 mg capsules
How to take Pradaxa
Pradaxa can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach. Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding.
Instructions for opening the blisters
The following pictogram illustrates how to take Pradaxa capsules out of the blister
Tear off one individual blister from the blister card along the perforated line
Peel off the backing foil and remove the capsule.
- Do not push the capsules through the blister foil.
- Do not peel off the blister foil until a capsule is required.
Instructions for the bottle
- Push and turn for opening.
- After removing the capsule, place the cap back on the bottle and tightly close the bottle right away after you take your dose.
Change of anticoagulant treatment
Without specific guidance from your doctor do not change your anticoagulant treatment.
If you take more Pradaxa than you should
Taking too much of this medicine increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. Specific treatment options are available.
If you forget to take Pradaxa
Prevention of blood clot formation after knee or hip replacement surgery
Continue with your remaining daily doses of Pradaxa at the same time of the next day.
Do not take a double dose to make up for a forgotten dose.
Treatment of blood clots and prevention of blood clots from reoccurring in children A forgotten dose can still be taken up to 6 hours prior to the next due dose.
A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose.
Do not double a dose to make up for a forgotten dose.
If you stop taking Pradaxa
Take Pradaxa exactly as prescribed. Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.
Contact your doctor if you experience indigestion after taking Pradaxa.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Pradaxa affects blood clotting, so most side effects are related to signs such as bruising or bleeding.
Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.
If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately. Your doctor may decide to keep you under closer observation or change your medicine.
Tell your doctor immediately, if you experience a serious allergic reaction which causes difficulty in breathing or dizziness.
Possible side effects are listed below, grouped by how likely they are to happen.
Prevention of blood clot formation after knee or hip replacement surgery
Common (may affect up to 1 in 10 people):
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- Unusual laboratory test results on liver function
Uncommon (may affect up to 1 in 100 people):
- Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), from piles, from the rectum, under the skin, into a joint, from or after an injury or after an operation
- Haematoma formation or bruising occurring after an operation
- Blood detected in the stools by a laboratory test
- A fall in the number of red cells in the blood
- A decrease in the proportion of blood cells
- Allergic reaction
- Vomiting
- Frequent loose or liquid bowel movements
- Feeling sick
- Wound secretion (liquid exuding from the surgical wound)
- Liver enzymes increased
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Rare (may affect up to 1 in 1 000 people):
- Bleeding
- Bleeding may happen in the brain, from a surgical incision, from the site of entry of an injection or from the site of entry of a catheter into a vein
- Blood-stained discharge from the site of entry of a catheter into a vein
- Coughing of blood or blood stained sputum
- A fall in the number of platelets in the blood
- A fall in the number of red cells in the blood after an operation
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Belly ache or stomach ache
- Indigestion
- Difficulty in swallowing
- Fluid exiting a wound
- Fluid exiting a wound after an operation
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Hair loss
Treatment of blood clots and prevention of blood clots from reoccurring in children
Common (may affect up to 1 in 10 people):
- A fall in the number of red cells in the blood
- A fall in the number of platelets in the blood
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Haematoma formation
- Nosebleed
- Reflux of gastric juice into the gullet
- Vomiting
- Feeling sick
- Frequent loose or liquid bowel movements
- Indigestion
- Hair loss
- Liver enzymes increased
Uncommon (may affect up to 1 in 100 people):
- Decrease in the number of white blood cells (which help to fight infections)
- Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Itching
- Coughing of blood or blood stained sputum
- Belly ache or stomach ache
- Inflammation of the gullet and stomach
- Allergic reaction
- Difficulty in swallowing
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Lack of white blood cells (which help to fight infections)
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Difficulty in breathing or wheezing
- Bleeding
- Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein
- Bleeding may happen from piles
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Unusual laboratory test results on liver function
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Pradaxa
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, blister or bottle after “EXP”. The expiry date refers to the last day of that month.
Blister: Store in the original package in order to protect from moisture.
Bottle:
Once opened, the medicine must be used within 4 months. Keep the bottle tightly closed.
Store in the original package in order to protect from moisture.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Pradaxa contains
- The active substance is dabigatran. Each hard capsule contains 75 mg dabigatran etexilate (as mesilate).
- The other ingredients are tartaric acid, acacia, hypromellose, dimeticone 350, talc, and hydroxypropylcellulose.
- The capsule shell contains carrageenan, potassium chloride, titanium dioxide, and hypromellose.
- The black printing ink contains shellac, iron oxide black and potassium hydroxide.
What Pradaxa looks like and contents of the pack
Pradaxa 75 mg are hard capsules (approx. 18 × 6 mm) with an opaque, white cap and an opaque, white body. The Boehringer Ingelheim logo is printed on the cap and “R75” on the body of the hard capsule.
This medicine is available in packs containing 10 × 1, 30 × 1 or 60 × 1 hard capsules in aluminium perforated unit dose blisters. Furthermore, Pradaxa is available in packs containing 60 × 1 hard capsules in aluminium perforated unit dose white blisters.
This medicine is also available in polypropylene (plastic) bottles with 60 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
and
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Lietuva
Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel: +370 5 2595942
България
Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ – клон България
Тел: +359 2 958 79 98
Luxembourg/Luxemburg
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Česká republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111
Magyarország
Boehringer Ingelheim RCV GmbH & Co KG
Magyarországi Fióktelepe
Tel: +36 1 299 8900
Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 88
Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Deutschland
Boehringer Ingelheim Pharma GmbH & Co. KG
Tel: +49 (0) 800 77 90 900
Nederland
Boehringer Ingelheim B.V.
Tel: +31 (0) 800 22 55 889
Eesti
Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Tel: +372 612 8000
Norge
Boehringer Ingelheim Danmark A/S NUF
Tlf: +47 66 76 13 00
Ελλάδα
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Österreich
Boehringer Ingelheim RCV GmbH & Co KG
Tel: +43 1 80 105-7870
España
Boehringer Ingelheim España S.A.
Tel: +34 93 404 51 00
Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 699
France
Boehringer Ingelheim France S.A.S.
Tél: +33 3 26 50 45 33
Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 00
Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 600
România
Boehringer Ingelheim RCV GmbH & Co KG
Viena-Sucursala Bucuresti
Tel: +40 21 302 2800
Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Slovenija
Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Tel: +386 1 586 40 00
Ísland
Vistor ehf.
Sími: +354 535 7000
Slovenská republika
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Tel: +421 2 5810 1211
Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102 800
Κύπρος
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Sverige
Boehringer Ingelheim AB
Tel: +46 8 721 21 00
Latvija
Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Tel: +371 67 240 011
United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
This leaflet was last approved in
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/.
Package leaflet: Pradaxa 110 mg hard capsules / dabigatran etexilate
1. What Pradaxa is and what it is used for
Pradaxa contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.
Pradaxa is used in adults to:
- prevent the formation of blood clots in the veins after knee or hip replacement surgery.
- prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor.
- treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occurring in the vein of your legs and lungs.
Pradaxa is used in children to:
- treat blood clots and to prevent blood clots from reoccurring.
2. What you need to know before you take Pradaxa
Do not take Pradaxa
- if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
- if you have severely reduced kidney function.
- if you are currently bleeding.
- if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
- if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
- if you are taking medicines to prevent blood clotting (e.g.warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open or while your heart beat is being restored to normal by a procedure called catheter ablation for atrial fibrillation.
- if you have a severely reduced liver function or liver disease which could possibly cause death.
- if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections.
- if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation.
- if you are taking dronedarone, a medicine used to treat abnormal heart beat.
- if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C
- if you have received an artificial heart valve which requires permanent blood thinning.
Warnings and precautions
Talk to your doctor before taking Pradaxa. You may also need to talk to your doctor during treatment with this medicine if you experience symptoms or if you have to undergo surgery.
Tell your doctor if you have or have had any medical conditions or illnesses, in particular any of those included in the following list:
- if you have an increased bleeding risk, such as:
▪ if you have been recently bleeding.
▪ if you have had a surgical tissue removal (biopsy) in the past month.
▪ if you have had a serious injury (e.g. a bone fracture, head injury or any injury requiring surgical treatment).
▪ if you are suffering from an inflammation of the gullet or stomach.
▪ if you have problems with reflux of gastric juice into the gullet.
▪ if you are receiving medicines which could increase the risk of bleeding. See ‘Other medicines and Pradaxa’ below.
▪ if you are taking anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam.
▪ if you are suffering from an infection of the heart (bacterial endocarditis).
▪ if you know you have decreased kidney function, or you are suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) / foaming urine).
▪ if you are older than 75 years.
▪ if you are an adult patient and weigh 50 kg or less.
▪ only if used for children: if the child has an infection around or within the brain.
- if you have had a heart attack or if you have been diagnosed with conditions that increase the risk to develop a heart attack.
- if you have a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.
Take special care with Pradaxa
- if you need to have an operation:
In this case Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
- if an operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
▪ it is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
▪ tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.
- if you fall or injure yourself during treatment, especially if you hit your head. Please seek urgent medical attention. You may need to be checked by a doctor, as you may be at increased risk of bleeding.
- if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.
Other medicines and Pradaxa
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular you should tell your doctor before taking Pradaxa, if you are taking one of the medicines listed below:
- Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid)
- Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin
- Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil).
If you are taking amiodarone, quinidine or verapamil containing medicines, your doctor may tell you to use a reduced dose of Pradaxa depending on the condition for which it is prescribed to you. See section 3.
- Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine)
- A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C)
- Anti-inflammatory and pain reliever medicines (e.g. acetylsalicylic acid, ibuprofen, diclofenac)
- St. John´s wort, a herbal medicine for depression
- Antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin- norepinephrine re-uptake inhibitors
- Rifampicin or clarithromycin (two antibiotics)
- Anti-viral medicines for AIDS (e.g. ritonavir)
- Certain medicines for treatment of epilepsy (e.g. carbamazepine, phenytoin)
Pregnancy and breast-feeding
The effects of Pradaxa on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant unless your doctor advises you that it is safe to do so. If you are a woman of child-bearing age, you should avoid becoming pregnant while you are taking Pradaxa.
You should not breast-feed while you are taking Pradaxa.
Driving and using machines
Pradaxa has no known effects on the ability to drive or use machines.
3. How to take Pradaxa
Pradaxa capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. Pradaxa coated granules are available for the treatment of children below 12 years as soon as they are able to swallow soft food.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Take Pradaxa as recommended for the following conditions:
Prevention of blood clot formation after knee or hip replacement surgery
The recommended dose is 220 mg once a day (taken as 2 capsules of 110 mg).
If your kidney function is decreased by more than half or if you are 75 years of age or older, the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).
If you are taking amiodarone, quinidine or verapamil containing medicines the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).
If you are taking verapamil containing medicines and your kidney function is decreased by more than half, you should be treated with a reduced dose of 75 mg Pradaxa because your bleeding risk may be increased.
For both surgery types, treatment should not be started if there is bleeding from the site of operation. If the treatment cannot be started until the day after surgery, dosing should be started with 2 capsules once a day.
After knee replacement surgery
You should start treatment with Pradaxa within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 10 days.
After hip replacement surgery
You should start treatment with Pradaxa within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 28-35 days.
Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats and Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the vein of your legs and lungs
The recommended dose is 300 mg taken as one 150 mg capsule twice a day.
If you are 80 years or older, the recommended dose is 220 mg taken as one 110 mg capsule twice a day.
If you are taking verapamil containing medicines, you should be treated with a reduced Pradaxa dose of 220 mg taken as one 110 mg capsule twice a day, because your bleeding risk may be increased.
If you have a potentially higher risk for bleeding, your doctor may decide to prescribe a dose of 220 mg taken as one 110 mg capsule twice a day.
You can continue to take this medicine if your heart beat needs to be restored to normal by a procedure called cardioversion. Take Pradaxa as your physician has told you.
If a medical device (stent) has been deployed in a blood vessel to keep it open in a procedure called percutaneous coronary intervention with stenting, you can be treated with Pradaxa after your physician has decided that normal control of blood coagulation is achieved. Take Pradaxa as your physician has told you.
Treatment of blood clots and prevention of blood clots from reoccurring in children
Pradaxa should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.
The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose as treatment progresses. Keep using all other medicines, unless your doctor tells you to stop using any.
Table 1 shows single and total daily Pradaxa doses in milligrams (mg). The doses depend on weight in kilograms (kg) and age in years of the patient.
Table 1:
Dosing table for Pradaxa capsules
Weight / age combinations
Single dose in mg
Total daily dose in mg
Weight in kg
Age in years
11 to less than 13 kg
8 to less than 9 years
13 to less than 16 kg
8 to less than 11 years
16 to less than 21 kg
8 to less than 14 years
21 to less than 26 kg
8 to less than 16 years
26 to less than 31 kg
8 to less than 18 years
31 to less than 41 kg
8 to less than 18 years
41 to less than 51 kg
8 to less than 18 years
51 to less than 61 kg
8 to less than 18 years
61 to less than 71 kg
8 to less than 18 years
71 to less than 81 kg
8 to less than 18 years
81 kg or greater
10 to less than 18 years
Single doses requiring combinations of more than one capsule:
300 mg:
two 150 mg capsules or four 75 mg capsules
260 mg:
one 110 mg plus one 150 mg capsule or one 110 mg plus two 75 mg capsules
220 mg:
two 110 mg capsules
185 mg:
one 75 mg plus one 110 mg capsule
150 mg:
one 150 mg capsule or two 75 mg capsules
How to take Pradaxa
Pradaxa can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach. Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding.
Instructions for opening the blisters
The following pictogram illustrates how to take Pradaxa capsules out of the blister
Tear off one individual blister from the blister card along the perforated line
Peel off the backing foil and remove the capsule.
- Do not push the capsules through the blister foil.
- Do not peel off the blister foil until a capsule is required.
Instructions for the bottle
- Push and turn for opening.
- After removing the capsule, place the cap back on the bottle and tightly close the bottle right away after you take your dose.
Change of anticoagulant treatment
Without specific guidance from your doctor do not change your anticoagulant treatment.
If you take more Pradaxa than you should
Taking too much of this medicine increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. Specific treatment options are available.
If you forget to take Pradaxa
Prevention of blood clot formation after knee or hip replacement surgery
Continue with your remaining daily doses of Pradaxa at the same time of the next day.
Do not take a double dose to make up for a forgotten dose.
Use in adults: Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats and treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the vein of your legs and lungs Use in children: Treatment of blood clots and prevention of blood clots from reoccurring A forgotten dose can still be taken up to 6 hours prior to the next due dose.
A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose.
Do not double a dose to make up for a forgotten dose.
If you stop taking Pradaxa
Take Pradaxa exactly as prescribed. Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.
Contact your doctor if you experience indigestion after taking Pradaxa.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Pradaxa affects blood clotting, so most side effects are related to signs such as bruising or bleeding.
Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.
If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately. Your doctor may decide to keep you under closer observation or change your medicine.
Tell your doctor immediately, if you experience a serious allergic reaction which causes difficulty in breathing or dizziness.
Possible side effects are listed below, grouped by how likely they are to happen.
Prevention of blood clot formation after knee or hip replacement surgery
Common (may affect up to 1 in 10 people):
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- Unusual laboratory test results on liver function
Uncommon (may affect up to 1 in 100 people):
- Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), from piles, from the rectum, under the skin, into a joint, from or after an injury or after an operation
- Haematoma formation or bruising occurring after an operation
- Blood detected in the stools by a laboratory test
- A fall in the number of red cells in the blood
- A decrease in the proportion of blood cells
- Allergic reaction
- Vomiting
- Frequent loose or liquid bowel movements
- Feeling sick
- Wound secretion (liquid exuding from the surgical wound)
- Liver enzymes increased
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Rare (may affect up to 1 in 1 000 people):
- Bleeding
- Bleeding may happen in the brain, from a surgical incision, from the site of entry of an injection or from the site of entry of a catheter into a vein
- Blood-stained discharge from the site of entry of a catheter into a vein
- Coughing of blood or blood stained sputum
- A fall in the number of platelets in the blood
- A fall in the number of red cells in the blood after an operation
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Belly ache or stomach ache
- Indigestion
- Difficulty in swallowing
- Fluid exiting a wound
- Fluid exiting a wound after an operation
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Hair loss
Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats
Common (may affect up to 1 in 10 people):
- Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the number of red cells in the blood
- Belly ache or stomach ache
- Indigestion
- Frequent loose or liquid bowel movements
- Feeling sick
Uncommon (may affect up to 1 in 100 people):
- Bleeding
- Bleeding may happen from piles, from the rectum, or in the brain.
- Haematoma formation
- Coughing of blood or blood stained sputum
- A fall in the number of platelets in the blood
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- Allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Vomiting
- Difficulty in swallowing
- Unusual laboratory test results on liver function
Rare (may affect up to 1 in 1 000 people):
- Bleeding may happen into a joint, from a surgical incision, from an injury, from the site of entry of an injection or from the site of entry of a catheter into a vein
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- A decrease in the proportion of blood cells
- Liver enzymes increased
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Hair loss
In a clinical trial the rate of heart attacks with Pradaxa was numerically higher than with warfarin. The overall occurrence was low.
Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from
re-occurring in the veins of your legs and/or lungs
Common (may affect up to 1 in 10 people):
- Bleeding may happen from the nose, into the stomach or bowel, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- Indigestion
Uncommon (may affect up to 1 in 100 people):
- Bleeding
- Bleeding may happen into a joint or from an injury
- Bleeding may happen from piles
- A fall in the number of red cells in the blood
- Haematoma formation
- Coughing of blood or blood stained sputum
- Allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Feeling sick
- Vomiting
- Belly ache or stomach ache
- Frequent loose or liquid bowel movements
- Unusual laboratory test results on liver function
- Liver enzymes increased
Rare (may affect up to 1 in 1 000 people):
- Bleeding may happen, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein or from the brain
- A fall in the number of platelets in the blood
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Difficulty in swallowing
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
- Hair loss
In the trial program the rate of heart attacks with Pradaxa was higher than with warfarin. The overall occurence was low. No imbalance in the rate of heart attacks was observed in patients treated with dabigatran versus patients treated with placebo.
Treatment of blood clots and prevention of blood clots from reoccurring in children
Common (may affect up to 1 in 10 people):
- A fall in the number of red cells in the blood
- A fall in the number of platelets in the blood
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Haematoma formation
- Nosebleed
- Reflux of gastric juice into the gullet
- Vomiting
- Feeling sick
- Frequent loose or liquid bowel movements
- Indigestion
- Hair loss
- Liver enzymes increased
Uncommon (may affect up to 1 in 100 people):
- Decrease in the number of white blood cells (which help to fight infections)
- Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Itching
- Coughing of blood or blood stained sputum
- Belly ache or stomach ache
- Inflammation of the gullet and stomach
- Allergic reaction
- Difficulty in swallowing
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Lack of white blood cells (which help to fight infections)
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Difficulty in breathing or wheezing
- Bleeding
- Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein
- Bleeding may happen from piles
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Unusual laboratory test results on liver function
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Pradaxa
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, blister or bottle after “EXP”. The expiry date refers to the last day of that month.
Blister: Store in the original package in order to protect from moisture.
Bottle:
Once opened, the medicine must be used within 4 months. Keep the bottle tightly closed.
Store in the original package in order to protect from moisture.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Pradaxa contains
- The active substance is dabigatran. Each hard capsule contains 110 mg dabigatran etexilate (as mesilate).
- The other ingredients are tartaric acid, acacia, hypromellose, dimeticone 350, talc, and hydroxypropylcellulose.
- The capsule shell contains carrageenan, potassium chloride, titanium dioxide, indigo carmine, and hypromellose.
- The black printing ink contains shellac, iron oxide black and potassium hydroxide.
What Pradaxa looks like and contents of the pack
Pradaxa 110 mg are hard capsules (approx. 19 × 7 mm) with an opaque, light blue-coloured cap and an opaque, light blue -coloured body. The Boehringer Ingelheim logo is printed on the cap and “R110” on the body of the hard capsule.
This medicine is available in packs containing 10 × 1, 30 × 1 or 60 × 1 hard capsules, a multipack containing 3 packs of 60 × 1 hard capsules (180 hard capsules) or a multipack containing 2 packs of 50 × 1 hard capsules (100 hard capsules) in aluminium perforated unit dose blisters. Furthermore, Pradaxa is available in packs containing 60 × 1 hard capsules in aluminium perforated unit dose white blisters.
This medicine is also available in polypropylene (plastic) bottles with 60 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
and
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Lietuva
Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel: +370 5 2595942
България
Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ – клон България
Тел: +359 2 958 79 98
Luxembourg/Luxemburg
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Česká republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111
Magyarország
Boehringer Ingelheim RCV GmbH & Co KG
Magyarországi Fióktelepe
Tel: +36 1 299 8900
Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 88
Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Deutschland
Boehringer Ingelheim Pharma GmbH & Co. KG
Tel: +49 (0) 800 77 90 900
Nederland
Boehringer Ingelheim B.V.
Tel: +31 (0) 800 22 55 889
Eesti
Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Tel: +372 612 8000
Norge
Boehringer Ingelheim Danmark A/S NUF
Tlf: +47 66 76 13 00
Ελλάδα
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Österreich
Boehringer Ingelheim RCV GmbH & Co KG
Tel: +43 1 80 105-7870
España
Boehringer Ingelheim España S.A.
Tel: +34 93 404 51 00
Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 699
France
Boehringer Ingelheim France S.A.S.
Tél: +33 3 26 50 45 33
Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 00
Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 600
România
Boehringer Ingelheim RCV GmbH & Co KG
Viena-Sucursala Bucuresti
Tel: +40 21 302 2800
Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Slovenija
Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Tel: +386 1 586 40 00
Ísland
Vistor ehf.
Sími: +354 535 7000
Slovenská republika
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Tel: +421 2 5810 1211
Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102 800
Κύπρος
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Sverige
Boehringer Ingelheim AB
Tel: +46 8 721 21 00
Latvija
Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Tel: +371 67 240 011
United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
This leaflet was last approved in
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/.
Package leaflet: Pradaxa 150 mg hard capsules / dabigatran etexilate
1. What Pradaxa is and what it is used for
Pradaxa contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.
Pradaxa is used in adults to:
- prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor.
- treat blood clots in the veins of your legs and lungs and to prevent blood clots from re-occurring in the vein of your legs and lungs.
Pradaxa is used in children to:
- treat blood clots and to prevent blood clots from reoccurring.
2. What you need to know before you take Pradaxa
Do not take Pradaxa
- if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
- if you have severely reduced kidney function.
- if you are currently bleeding.
- if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
- if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
- if you are taking medicines to prevent blood clotting (e.g.warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open or while your heart beat is being restored to normal by a procedure called catheter ablation for atrial fibrillation.
- if you have a severely reduced liver function or liver disease which could possibly cause death.
- if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections.
- if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation.
- if you are taking dronedarone, a medicine used to treat abnormal heart beat.
- if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C
- if you have received an artificial heart valve which requires permanent blood thinning.
Warnings and precautions
Talk to your doctor before taking Pradaxa. You may also need to talk to your doctor during treatment with this medicine if you experience symptoms or if you have to undergo surgery.
Tell your doctor if you have or have had any medical conditions or illnesses, in particular any of those included in the following list:
- if you have an increased bleeding risk, such as:
▪ if you have been recently bleeding.
▪ if you have had a surgical tissue removal (biopsy) in the past month.
▪ if you have had a serious injury (e.g. a bone fracture, head injury or any injury requiring surgical treatment).
▪ if you are suffering from an inflammation of the gullet or stomach.
▪ if you have problems with reflux of gastric juice into the gullet.
▪ if you are receiving medicines which could increase the risk of bleeding. See ‘Other medicines and Pradaxa’ below.
▪ if you are taking anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam.
▪ if you are suffering from an infection of the heart (bacterial endocarditis).
▪ if you know you have decreased kidney function, or you are suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) / foaming urine).
▪ if you are older than 75 years.
▪ if you are an adult patient and weigh 50 kg or less.
▪ only if used for children: if the child has an infection around or within the brain.
- if you have had a heart attack or if you have been diagnosed with conditions that increase the risk to develop a heart attack.
- if you have a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.
Take special care with Pradaxa
- if you need to have an operation:
In this case Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
- if an operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
▪ it is very important to take Pradaxa before and after the operation exactly at the times you have been told by your doctor.
▪ tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.
- if you fall or injure yourself during treatment, especially if you hit your head. Please seek urgent medical attention. You may need to be checked by a doctor, as you may be at increased risk of bleeding.
- if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.
Other medicines and Pradaxa
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular you should tell your doctor before taking Pradaxa, if you are taking one of the medicines listed below:
- Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid)
- Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin
- Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil).
If you are taking verapamil containing medicines, your doctor may tell you to use a reduced dose of Pradaxa depending on the condition for which it is prescribed to you. See section 3.
- Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine)
- A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C)
- Anti-inflammatory and pain reliever medicines (e.g. acetylsalicylic acid, ibuprofen, diclofenac)
- St. John´s wort, a herbal medicine for depression
- Antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin- norepinephrine re-uptake inhibitors
- Rifampicin or clarithromycin (two antibiotics)
- Anti-viral medicines for AIDS (e.g. ritonavir)
- Certain medicines for treatment of epilepsy (e.g. carbamazepine, phenytoin)
Pregnancy and breast-feeding
The effects of Pradaxa on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant unless your doctor advises you that it is safe to do so. If you are a woman of child-bearing age, you should avoid becoming pregnant while you are taking Pradaxa.
You should not breast-feed while you are taking Pradaxa.
Driving and using machines
Pradaxa has no known effects on the ability to drive or use machines.
3. How to take Pradaxa
Pradaxa capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. Pradaxa coated granules are available for the treatment of children below 12 years as soon as they are able to swallow soft food.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Take Pradaxa as recommended for the following conditions:
Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats and Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the vein of your legs and lungs
The recommended dose is 300 mg taken as one 150 mg capsule twice a day.
If you are 80 years or older, the recommended dose is 220 mg taken as one 110 mg capsule twice daily.
If you are taking verapamil containing medicines, you should be treated with a reduced Pradaxa dose of 220 mg taken as one 110 mg capsule twice a day, because your bleeding risk may be increased.
If you have a potentially higher risk for bleeding, your doctor may decide to prescribe a dose of 220 mg taken as one 110 mg capsule twice a day.
You can continue to take this medicine if your heart beat needs to be restored to normal by a procedure called cardioversion or by a procedure called catheter ablation for atrial fibrillation. Take Pradaxa as your physician has told you.
If a medical device (stent) has been deployed in a blood vessel to keep it open in a procedure called percutaneous coronary intervention with stenting, you can be treated with Pradaxa after your physician has decided that normal control of blood coagulation is achieved. Take Pradaxa as your physician has told you.
Treatment of blood clots and prevention of blood clots from reoccurring in children
Pradaxa should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.
The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose as treatment progresses. Keep using all other medicines, unless your doctor tells you to stop using any.
Table 1 shows single and total daily Pradaxa doses in milligrams (mg). The doses depend on weight in kilograms (kg) and age in years of the patient.
Table 1:
Dosing table for Pradaxa capsules
Weight / age combinations
Single dose in mg
Total daily dose in mg
Weight in kg
Age in years
11 to less than 13 kg
8 to less than 9 years
13 to less than 16 kg
8 to less than 11 years
16 to less than 21 kg
8 to less than 14 years
21 to less than 26 kg
8 to less than 16 years
26 to less than 31 kg
8 to less than 18 years
31 to less than 41 kg
8 to less than 18 years
41 to less than 51 kg
8 to less than 18 years
51 to less than 61 kg
8 to less than 18 years
61 to less than 71 kg
8 to less than 18 years
71 to less than 81 kg
8 to less than 18 years
81 kg or greater
10 to less than 18 years
Single doses requiring combinations of more than one capsule:
300 mg:
two 150 mg capsules or four 75 mg capsules
260 mg:
one 110 mg plus one 150 mg capsule or one 110 mg plus two 75 mg capsules
220 mg:
two 110 mg capsules
185 mg:
one 75 mg plus one 110 mg capsule
150 mg:
one 150 mg capsule or two 75 mg capsules
How to take Pradaxa
Pradaxa can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach. Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding.
Instructions for opening the blisters
The following pictogram illustrates how to take Pradaxa capsules out of the blister
Tear off one individual blister from the blister card along the perforated line
Peel off the backing foil and remove the capsule.
- Do not push the capsules through the blister foil.
- Do not peel off the blister foil until a capsule is required.
Instructions for the bottle
- Push and turn for opening.
- After removing the capsule, place the cap back on the bottle and tightly close the bottle right away after you take your dose.
Change of anticoagulant treatment
Without specific guidance from your doctor do not change your anticoagulant treatment.
If you take more Pradaxa than you should
Taking too much of this medicine increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. Specific treatment options are available.
If you forget to take Pradaxa
A forgotten dose can still be taken up to 6 hours prior to the next due dose.
A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose.
Do not double a dose to make up for a forgotten dose.
If you stop taking Pradaxa
Take Pradaxa exactly as prescribed. Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.
Contact your doctor if you experience indigestion after taking Pradaxa.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Pradaxa affects blood clotting, so most side effects are related to signs such as bruising or bleeding.
Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.
If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately. Your doctor may decide to keep you under closer observation or change your medicine.
Tell your doctor immediately, if you experience a serious allergic reaction which causes difficulty in breathing or dizziness.
Possible side effects are listed below, grouped by how likely they are to happen.
Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats
Common (may affect up to 1 in 10 people):
- Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the number of red cells in the blood
- Belly ache or stomach ache
- Indigestion
- Frequent loose or liquid bowel movements
- Feeling sick
Uncommon (may affect up to 1 in 100 people):
- Bleeding
- Bleeding may happen from piles, from the rectum, or in the brain.
- Haematoma formation
- Coughing of blood or blood stained sputum
- A fall in the number of platelets in the blood
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- Allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Vomiting
- Difficulty in swallowing
- Unusual laboratory test results on liver function
Rare (may affect up to 1 in 1 000 people):
- Bleeding may happen into a joint, from a surgical incision, from an injury, from the site of entry of an injection or from the site of entry of a catheter into a vein
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- A decrease in the proportion of blood cells
- Liver enzymes increased
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Hair loss
In a clinical trial the rate of heart attacks with Pradaxa was numerically higher than with warfarin. The overall occurence was low.
Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occurring in the veins of your legs and/or lungs
Common (may affect up to 1 in 10 people):
- Bleeding may happen from the nose, into the stomach or bowel, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- Indigestion
Uncommon (may affect up to 1 in 100 people):
- Bleeding
- Bleeding may happen into a joint or from an injury
- Bleeding may happen from piles
- A fall in the number of red cells in the blood
- Haematoma formation
- Coughing of blood or blood stained sputum
- Allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Itching
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Inflammation of the gullet and stomach
- Reflux of gastric juice into the gullet
- Feeling sick
- Vomiting
- Belly ache or stomach ache
- Frequent loose or liquid bowel movements
- Unusual laboratory test results on liver function
- Liver enzymes increased
Rare (may affect up to 1 in 1 000 people):
- Bleeding may happen, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein or from the brain
- A fall in the number of platelets in the blood
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Difficulty in swallowing
Not known (frequency cannot be estimated from the available data):
- Difficulty in breathing or wheezing
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Decreases in the number or even lack of white blood cells (which help to fight infections)
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
- Hair loss
In the trial program the rate of heart attacks with Pradaxa was higher than with warfarin. The overall occurrence was low. No imbalance in the rate of heart attacks was observed in patients treated with dabigatran versus patients treated with placebo.
Treatment of blood clots and prevention of blood clots from reoccurring in children
Common (may affect up to 1 in 10 people):
- A fall in the number of red cells in the blood
- A fall in the number of platelets in the blood
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Haematoma formation
- Nosebleed
- Reflux of gastric juice into the gullet
- Vomiting
- Feeling sick
- Frequent loose or liquid bowel movements
- Indigestion
- Hair loss
- Liver enzymes increased
Uncommon (may affect up to 1 in 100 people):
- Decrease in the number of white blood cells (which help to fight infections)
- Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Itching
- Coughing of blood or blood stained sputum
- Belly ache or stomach ache
- Inflammation of the gullet and stomach
- Allergic reaction
- Difficulty in swallowing
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Lack of white blood cells (which help to fight infections)
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Difficulty in breathing or wheezing
- Bleeding
- Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein
- Bleeding may happen from piles
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Unusual laboratory test results on liver function
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Pradaxa
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, blister or bottle after “EXP”. The expiry date refers to the last day of that month.
Blister: Store in the original package in order to protect from moisture.
Bottle:
Once opened, the medicine must be used within 4 months. Keep the bottle tightly closed.
Store in the original package in order to protect from moisture.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Pradaxa contains
- The active substance is dabigatran. Each hard capsule contains 150 mg dabigatran etexilate (as mesilate).
- The other ingredients are tartaric acid, acacia, hypromellose, dimeticone 350, talc, and hydroxypropylcellulose.
- The capsule shell contains carrageenan, potassium chloride, titanium dioxide, indigo carmine, and hypromellose.
- The black printing ink contains shellac, iron oxide black and potassium hydroxide.
What Pradaxa looks like and contents of the pack
Pradaxa 150 mg are hard capsules (approx. 22 × 8 mm) with an opaque, light blue-coloured cap and an opaque, white body. The Boehringer Ingelheim logo is printed on the cap and “R150” on the body of the hard capsule.
This medicine is available in packs containing 10 × 1, 30 × 1 or 60 × 1 hard capsules, a multipack containing 3 packs of 60 × 1 hard capsules (180 hard capsules) or a multipack containing 2 packs of 50 × 1 hard capsules (100 hard capsules) in aluminium perforated unit dose blisters. Furthermore, Pradaxa is available in packs containing 60 × 1 hard capsules in aluminium perforated unit dose white blisters.
This medicine is also available in polypropylene (plastic) bottles with 60 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
and
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Lietuva
Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel: +370 5 2595942
България
Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ – клон България
Тел: +359 2 958 79 98
Luxembourg/Luxemburg
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Česká republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111
Magyarország
Boehringer Ingelheim RCV GmbH & Co KG
Magyarországi Fióktelepe
Tel: +36 1 299 8900
Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 88
Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Deutschland
Boehringer Ingelheim Pharma GmbH & Co. KG
Tel: +49 (0) 800 77 90 900
Nederland
Boehringer Ingelheim B.V.
Tel: +31 (0) 800 22 55 889
Eesti
Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Tel: +372 612 8000
Norge
Boehringer Ingelheim Danmark A/S NUF
Tlf: +47 66 76 13 00
Ελλάδα
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Österreich
Boehringer Ingelheim RCV GmbH & Co KG
Tel: +43 1 80 105-7870
España
Boehringer Ingelheim España S.A.
Tel: +34 93 404 51 00
Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 699
France
Boehringer Ingelheim France S.A.S.
Tél: +33 3 26 50 45 33
Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 00
Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 600
România
Boehringer Ingelheim RCV GmbH & Co KG
Viena-Sucursala Bucuresti
Tel: +40 21 302 2800
Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Slovenija
Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Tel: +386 1 586 40 00
Ísland
Vistor ehf.
Sími: +354 535 7000
Slovenská republika
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Tel: +421 2 5810 1211
Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102 800
Κύπρος
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Sverige
Boehringer Ingelheim AB
Tel: +46 8 721 21 00
Latvija
Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Tel: +371 67 240 011
United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
This leaflet was last approved in
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/.
Package leaflet: Pradaxa 20 mg coated granules / Pradaxa 30 mg coated granules / Pradaxa 40 mg coated granules / Pradaxa 50 mg coated granules / Pradaxa 110 mg coated granules / Pradaxa 150 mg coated granules
1. What Pradaxa is and what it is used for
2. What you need to know before your child takes Pradaxa
3. How to take Pradaxa
4. Possible side effects
5. How to store Pradaxa
6. Contents of the pack and other information
1.
What Pradaxa is and what it is used for
Pradaxa contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.
Pradaxa is used in children to treat blood clots and to prevent blood clots from reoccurring.
2.
What you need to know before your child takes Pradaxa
Do not use Pradaxa
- if your child is allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
- if your child has severely reduced kidney function.
- if your child is currently bleeding.
- if your child has a disease in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
- if your child has an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
- if your child is given medicines to prevent blood clotting (e.g.warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment or while having a venous or arterial line and your child gets heparin through this line to keep it open.
- if your child has a severely reduced liver function or liver disease which could possibly cause death.
- if your child is given oral ketoconazole or itraconazole, medicines to treat fungal infections.
- if your child is given oral cyclosporine, a medicine to prevent organ rejection after transplantation.
- if your child is given dronedarone, a medicine used to treat abnormal heart beat.
- if your child is given a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C
- if your child has received an artificial heart valve which requires permanent blood thinning.
Warnings and precautions
Talk to your child’s doctor before you give your child Pradaxa. You may also need to talk to your child’s doctor during treatment with this medicine if your child experiences symptoms or if your child has to undergo surgery.
Tell your child’s doctor if your child has or has had any medical conditions or illnesses, in particular any of those included in the following list:
- if your child has an increased bleeding risk, such as:
▪ if your child has been recently bleeding.
▪ if your child has had a surgical tissue removal (biopsy) in the past month.
▪ if your child has had a serious injury (e.g. a bone fracture, head injury or any injury requiring surgical treatment).
▪ if your child is suffering from an inflammation of the gullet or stomach.
▪ if your child has problems with reflux of gastric juice into the gullet.
▪ if your child is receiving medicines which could increase the risk of bleeding. See ‘Other medicines and Pradaxa’ below.
▪ if your child is given anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam.
▪ if your child is suffering from an infection of the heart (bacterial endocarditis).
▪ if you know your child has decreased kidney function, or your child is suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark- coloured (concentrated) / foaming urine).
▪ if your child has an infection around or within the brain.
- if your child has had a heart attack or if your child has been diagnosed with conditions that increase the risk to develop a heart attack.
- if your child has a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.
Take special care with Pradaxa
- if your child needs to have an operation:
In this case Pradaxa will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to give Pradaxa before and after the operation exactly at the times you have been told by your child’s doctor.
- if an operation involves a catheter or injection into your child’s spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
▪ it is very important to give Pradaxa before and after the operation exactly at the times you have been told by your child’s doctor.
▪ tell your child’s doctor immediately if your child gets numbness or weakness of the legs or problems with his/her bowel or bladder after the end of anaesthesia, because urgent care is necessary.
- if your child falls or injures himself/herself during treatment, especially if your child hits his/her head. Please seek urgent medical attention. Your child may need to be checked by a doctor, as your child may be at increased risk of bleeding.
- if you know that your child has a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your child’s doctor who will decide if the treatment may need to be changed.
Other medicines and Pradaxa
Tell your child’s doctor or pharmacist if your child is given or has recently been given other medicines. In particular you should tell your child’s doctor before taking Pradaxa, if your child is given one of the medicines listed below:
- Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid)
- Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin
- Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil).
- Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine)
- A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C)
- Anti-inflammatory and pain reliever medicines (e.g. acetylsalicylic acid, ibuprofen, diclofenac)
- St. John´s wort, a herbal medicine for depression
- Antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin- norepinephrine re-uptake inhibitors
- Rifampicin or clarithromycin (two antibiotics)
- Anti-viral medicines for AIDS (e.g. ritonavir)
- Certain medicines for treatment of epilepsy (e.g. carbamazepine, phenytoin)
Pradaxa with food and drink
Do not mix Pradaxa coated granules with milk or soft food containing milk products. Only use this medicine with apple juice or one of the soft foods mentioned in the instructions for administration at the end of the package leaflet.
Pregnancy and breast-feeding
This medicine is intended to be used in children below the age of 12 years. Information regarding pregnancy and breast-feeding may not be relevant in the context of your child’s treatment.
The effects of Pradaxa on pregnancy and the unborn child are not known. A pregnant woman should not take this medicine unless her doctor advises her that it is safe to do so. A woman of child-bearing age should avoid becoming pregnant while she is taking Pradaxa.
Breast-feeding should be stopped during treatment with Pradaxa.
Driving and using machines
Pradaxa has no known effects on the ability to drive or use machines.
3.
How to take Pradaxa
Pradaxa coated granules can be used for children below 12 years as soon as they are able to swallow soft food. Pradaxa capsules are available for the treatment of children aged 8 years or older.
Always give this medicine exactly as your child’s doctor has told you. Check with your child’s doctor if you are not sure.
Pradaxa should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.
The recommended dose depends on weight and age. Your child’s doctor will determine the correct dose. Your child’s doctor may adjust the dose as treatment progresses. Your child must keep using all other medicines, unless your child’s doctor tells you to stop using any.
Table 1 shows single and total daily Pradaxa doses in milligrams (mg) for patients below 12 months.
The doses depend on weight in kilograms (kg) and age in months of the patient.
Table 1:
Dosing table for Pradaxa coated granules for patients below 12 months
Weight / age combinations
Single dose in mg
Total daily dose in mg
Weight in kg
Age in MONTHS
2.5 to less than 3 kg
4 to less than 5 months
3 to less than 4 kg
3 to less than 6 months
4 to less than 5 kg
1 to less than 3 months
3 to less than 8 months
8 to less than 10 months
5 to less than 7 kg
0 to less than 1 months
1 to less than 5 months
5 to less than 8 months
8 to less than 12 months
7 to less than 9 kg
3 to less than 4 months
4 to less than 9 months
9 to less than 12 months
9 to less than 11 kg
5 to less than 6 months
6 to less than 11 months
11 to less than 12 months
11 to less than 13 kg
8 to less than 10 months
10 to less than 12 months
13 to less than 16 kg
10 to less than 11 months
11 to less than 12 months
Convenient sachet combinations to achieve the single doses recommended in the dosing table are provided below. Other combinations are possible.
20 mg: One 20 mg sachet
60 mg: Two 30 mg sachets
30 mg: One 30 mg sachet
70 mg: One 30 mg plus one 40 mg sachet
40 mg: One 40 mg sachet
80 mg: Two 40 mg sachets
50 mg: One 50 mg sachet
100 mg: Two 50 mg sachets
Table 2 shows single and total daily Pradaxa doses in milligrams (mg) for patients from 1 year to less than 12 years. The doses depend on weight in kilograms (kg) and age in years of the patient.
Table 2:
Dosing table for Pradaxa coated granules for patients from 1 year to less than 12 years
Weight / age combinations
Single dose in mg
Total daily dose in mg
Weight in kg
Age in YEARS
5 to less than 7 kg
1 to less than 2 years
7 to less than 9 kg
1 to less than 2 years
2 to less than 4 years
9 to less than 11 kg
1 to less than 1.5 years
1.5 to less than 7 years
11 to less than 13 kg
1 to less than 1.5 years
1.5 to less than 2.5 years
2.5 to less than 9 years
13 to less than 16 kg
1 to less than 1.5 years
1.5 to less than 2 years
2 to less than 12 years
16 to less than 21 kg
1 to less than 2 years
2 to less than 12 years
21 to less than 26 kg
1.5 to less than 2 years
2 to less than 12 years
26 to less than 31 kg
2.5 to less than 12 years
31 to less than 41 kg
2.5 to less than 12 years
41 to less than 51 kg
4 to less than 12 years
51 to less than 61 kg
5 to less than 12 years
61 to less than 71 kg
6 to less than 12 years
71 to less than 81 kg
7 to less than 12 years above 81 kg
10 to less than 12 years
Convenient sachet combinations to achieve the single doses recommended in the dosing table are provided below. Other combinations are possible.
50 mg: One 50 mg sachet
140 mg: One 30 mg plus one 110 mg sachet
60 mg: Two 30 mg sachets
180 mg: One 30 mg plus one 150 mg sachet
70 mg: One 30 mg plus one 40 mg sachet
220 mg: Two 110 mg sachets
80 mg: Two 40 mg sachets
260 mg: One 110 mg plus one 150 mg sachet
100 mg: Two 50 mg sachets
300 mg: Two 150 mg sachets
110 mg: One 110 mg sachet
Method and route of administration
This medicine is given together with apple juice or one of the soft food options mentioned in the instructions for administration. Do not mix this medicine with milk or soft food containing milk products.
Detailed instructions for the use of this medicine are provided in ‘Instructions for administration’ at the end of the package leaflet.
Change of anticoagulant treatment
Without specific guidance from your child’s doctor do not change your child’s anticoagulant treatment.
If you give more Pradaxa than you should
Taking too much of this medicine increases the risk of bleeding. Contact your child’s doctor immediately if you have given too much of it. Specific treatment options are available.
If you forget to give your child Pradaxa
A forgotten dose can still be given up to 6 hours prior to the next due dose.
A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose.
Do not give a double dose to make up for a forgotten dose.
If a dose has only been taken partially, do not attempt to administer a second dose at that time-point.
Give the next dose as scheduled approximately 12 hours later.
If you stop giving Pradaxa
Give Pradaxa exactly as prescribed. Do not stop giving this medicine without talking to your child’s doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.
Contact your child’s doctor if your child experiences indigestion after giving Pradaxa.
If you have any further questions on the use of this medicine, ask your child’s doctor or pharmacist.
4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Pradaxa affects blood clotting, so most side effects are related to signs such as bruising or bleeding.
Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.
If your child experiences any bleeding event that does not stop by itself or if your child experiences signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your child’s doctor immediately. Your child’s doctor may decide to keep your child under closer observation or change the medicine.
Tell your child’s doctor immediately, if your child experiences a serious allergic reaction which causes difficulty in breathing or dizziness.
Possible side effects are listed below, grouped by how likely they are to happen.
Common (may affect up to 1 in 10 people):
- A fall in the number of red cells in the blood
- A fall in the number of platelets in the blood
- Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction
- Sudden change of the skin which affects its colour and appearance
- Haematoma formation
- Nosebleed
- Reflux of gastric juice into the gullet
- Vomiting
- Feeling sick
- Frequent loose or liquid bowel movements
- Indigestion
- Hair loss
- Liver enzymes increased
Uncommon (may affect up to 1 in 100 people):
- Decrease in the number of white blood cells (which help to fight infections)
- Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin
- A fall in the amount of haemoglobin in the blood (the substance in the red blood cells)
- A decrease in the proportion of blood cells
- Itching
- Coughing of blood or blood stained sputum
- Belly ache or stomach ache
- Inflammation of the gullet and stomach
- Allergic reaction
- Difficulty in swallowing
- Yellowing of the skin or whites of the eyes, caused by liver or blood problems
Not known (frequency cannot be estimated from the available data):
- Lack of white blood cells (which help to fight infections)
- Serious allergic reaction which causes difficulty in breathing or dizziness
- Serious allergic reaction which causes swelling of the face or throat
- Difficulty in breathing or wheezing
- Bleeding
- Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein
- Bleeding may happen from piles
- Ulcer in the stomach or bowel (incl. ulcer in the gullet)
- Unusual laboratory test results on liver function
Reporting of side effects
If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5.
How to store Pradaxa
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
Before first use, do not open the aluminium bag containing the sachets with the Pradaxa coated granules in order to protect from moisture.
Once the aluminium bag containing the sachets with the coated granules and the desiccant is opened, the medicine must be used within 6 months. The opened sachet cannot be stored and must be used immediately after opening.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
Contents of the pack and other information
What Pradaxa contains
- The active substance is dabigatran. Each sachet of Pradaxa 20 mg coated granules contains coated granules with 20 mg dabigatran etexilate (as mesilate).
- The active substance is dabigatran. Each sachet of Pradaxa 30 mg coated granules contains coated granules with 30 mg dabigatran etexilate (as mesilate).
- The active substance is dabigatran. Each sachet of Pradaxa 40 mg coated granules contains coated granules with 40 mg dabigatran etexilate (as mesilate).
- The active substance is dabigatran. Each sachet of Pradaxa 50 mg coated granules contains
coated granules with 50 mg dabigatran etexilate (as mesilate).
- The active substance is dabigatran. Each sachet of Pradaxa 110 mg coated granules contains coated granules with 110 mg dabigatran etexilate (as mesilate).
- The active substance is dabigatran. Each sachet of Pradaxa 150 mg coated granules contains coated granules with 150 mg dabigatran etexilate (as mesilate).
- The other ingredients are tartaric acid, acacia, hypromellose, dimeticone 350, talc and hydroxypropylcellulose.
What Pradaxa looks like and contents of the pack
The sachets of Pradaxa coated granules contain yellowish coated granules.
Each pack of this medicine contains an aluminium bag which in turn contains 60 silver-coloured aluminium sachets with Pradaxa coated granules and a desiccant (labelled “DO NOT EAT” including pictogram and “SILICA GEL”).
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Lietuva
Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel: +370 5 2595942
България
Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ – клон България
Тел: +359 2 958 79 98
Luxembourg/Luxemburg
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Česká republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111
Magyarország
Boehringer Ingelheim RCV GmbH & Co KG
Magyarországi Fióktelepe
Tel: +36 1 299 8900
Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 88
Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Deutschland
Boehringer Ingelheim Pharma GmbH & Co. KG
Tel: +49 (0) 800 77 90 900
Nederland
Boehringer Ingelheim B.V.
Tel: +31 (0) 800 22 55 889
Eesti
Boehringer Ingelheim RCV GmbH & Co KG
Eesti filiaal
Tel: +372 612 8000
Norge
Boehringer Ingelheim Danmark A/S NUF
Tlf: +47 66 76 13 00
Ελλάδα
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Österreich
Boehringer Ingelheim RCV GmbH & Co KG
Tel: +43 1 80 105-7870
España
Boehringer Ingelheim España S.A.
Tel: +34 93 404 51 00
Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 699
France
Boehringer Ingelheim France S.A.S.
Tél: +33 3 26 50 45 33
Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 00
Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 600
România
Boehringer Ingelheim RCV GmbH & Co KG
Viena-Sucursala Bucuresti
Tel: +40 21 302 2800
Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Slovenija
Boehringer Ingelheim RCV GmbH & Co KG
Podružnica Ljubljana
Tel: +386 1 586 40 00
Ísland
Vistor ehf.
Sími: +354 535 7000
Slovenská republika
Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka
Tel: +421 2 5810 1211
Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102 800
Κύπρος
Boehringer Ingelheim Ελλάς Μονοπρόσωπη
Α.Ε.
Tηλ: +30 2 10 89 06 300
Sverige
Boehringer Ingelheim AB
Tel: +46 8 721 21 00
Latvija
Boehringer Ingelheim RCV GmbH & Co KG
Latvijas filiāle
Tel: +371 67 240 011
United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
This leaflet was last approved in
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu/.
Instructions for administration
Do not administer Pradaxa coated granules
- via syringes or feeding tubes
- with other than the soft foods or apple juice as indicated below
Administer Pradaxa coated granules either with soft foods or apple juice. The instructions are provided below under A) for soft foods and B) for apple juice.
The prepared medicine should be given before meals in order to ensure that the patient takes the full dose.
Administer the prepared medicine to the patient immediately or within 30 minutes after mixing. Do not give this medicine if it has been in contact with the food or apple juice for more than 30 minutes.
In case of an incomplete intake of the prepared medicine, do not apply a second dose, wait until the next dosing time-point.
A)
Administration of Pradaxa coated granules with soft foods
The food should be at room temperature before mixing with the coated granules. The medicine can be administered with one of the following soft foods:
- Mashed carrots
- Apple sauce (for administration with apple juice see B)
- Mashed banana
Do not use soft food containing milk products.
Step 1 – Prepare cup or bowl
- Transfer two teaspoons of the soft food into a small cup or bowl.
Step 2 – Collect sachet(s)
- Upon first opening, open the silver aluminium bag by cutting at the top using scissors. The aluminium bag includes 60 silver-coloured sachets (medicine) and one desiccant with the imprint “DO NOT EAT” including pictogram and “SILICA GEL”.
- Do not open or consume the desiccant.
- Collect the required number of sachets with Pradaxa coated granules according to the prescribed dose.
- Put the unused sachets back into the aluminium bag.
Step 3 – Open sachet(s)
- Take the sachet containing the Pradaxa coated granules.
- Tap the sachet on the table to ensure that the contents settle to the bottom.
- Keep the sachet in an upright position.
- Open the sachet by cutting at the top using scissors.
Step 4 – Pour sachet(s) content
- Empty the entire content of the sachet into the small cup or bowl containing the soft food.
- Repeat Steps 3 and 4 if more than one sachet is needed.
Step 5 – Stir soft food to mix coated granules
- Stir soft food with the feeding spoon to thoroughly mix the coated granules with the soft food.
Step 6 – Administer soft food
- Administer the soft food with the coated granules to the patient immediately using the feeding spoon.
- Assure that all soft food is eaten.
B)
Administration of Pradaxa coated granules with apple juice
Step 1 – Have a cup of apple juice ready before the next step
Step 2 – Collect sachet(s)
- Upon first opening, open the silver aluminium bag by cutting at the top using scissors. The aluminium bag includes 60 silver-coloured sachets (medicine) and one desiccant with the imprint “DO NOT EAT” including pictogram and “SILICA GEL”.
- Do not open or consume the desiccant.
- Collect the required number of sachets with Pradaxa coated granules according to the prescribed dose.
- Put the unused sachets back into the aluminium bag.
Step 3 – Open sachet(s)
- Take the sachet containing the Pradaxa coated granules.
- Tap the sachet on the table to ensure that the contents settle to the bottom.
- Keep the sachet in an upright position.
- Open the sachet by cutting at the top using scissors.
Step 4 – Administer Pradaxa coated granules with apple juice
- Administer all of the coated granules directly from the sachet or using a feeding spoon into the child’s mouth and offer the child as much apple juice as needed to swallow the coated granules.
- Inspect child’s mouth to ensure that all coated granules are swallowed.
- Optional: If the Pradaxa coated granules are mixed in the apple juice cup, start with a small amount of apple juice (that your child is likely to drink completely) and ensure that all coated granules are taken. If coated granules are sticking to the cup, add another small amount of apple juice and again apply to your child. Repeat until no remaining coated granules are sticking to the cup.
PATIENT ALERT CARD [for Pradaxa 75 mg / 110 mg / 150 mg capsules]
Pradaxa® capsules dabigatran etexilate
- This card should be with you / the caregiver at all times
- Make sure to use the latest version
[xxxx 20xx]
[Boehringer Ingelheim logo]
Dear Patient / Caregiver of a paediatric patient,
Your / your child’s doctor has initiated treatment with Pradaxa®. In order to use Pradaxa® safely, please consider the important information in the package leaflet.
As this patient alert card contains important information about your / your child’s treatment, this card should be with you / your child at all times to inform healthcare professionals about your / your child’s intake of Pradaxa®.
[Pradaxa logo]
Pradaxa® Information for Patients / Caregivers of paediatric patients
About your / your child’s treatment
- Pradaxa® thins the blood. It is used to treat existing blood clots or to prevent the formation of dangerous blood clots.
- Follow your / your child’s doctor’s instructions when taking Pradaxa®. Never skip a dose or stop the intake of Pradaxa® without talking to your / your child’s doctor.
- Inform your / your child’s doctor about all medicines you / your child are / is currently taking.
- Inform your / your child’s doctor about the intake of Pradaxa® before any surgery / invasive procedure.
- Pradaxa® capsules can be taken with or without food. The capsule should be swallowed whole with a glass of water. The capsule must not be broken or chewed and the pellets must not be emptied from the capsule.
When to seek medical advice
- Taking Pradaxa® may increase the risk of bleeding. Speak to your / your child’s doctor immediately if you / your child experience(s) signs and symptoms of bleeding such as: swelling, discomfort, unusual pain or headache, dizziness, paleness, weakness, unusual bruising, nosebleeds, bleeding of gums, unusual long bleeding cuts, abnormal menstrual flow or vaginal bleeding, blood in the urine which may be pink or brown, red/black stools, coughing up blood, vomiting blood or coffee ground like material.
- In case of fall or injury, especially if the head is hit, urgently seek medical advice.
- Do not stop intake of Pradaxa® without talking to your / your child’s doctor, if you / your child experience(s) heartburn, nausea, vomiting, stomach discomfort, bloating or upper abdominal pain.
Pradaxa® Information for Healthcare Professionals
- Pradaxa® is an oral anticoagulant (direct thrombin inhibitor).
- Pradaxa® may need to be stopped in advance of surgical or other invasive procedures.
- In case of major bleeding events, Pradaxa® must be stopped immediately.
- A specific reversal agent (idarucizumab) is available for adult patients. The efficacy and safety of the specific reversal agent idarucizumab have not been established in paediatric patients. For details and more advice to antagonise the anticoagulant effect of Pradaxa® please refer to the Summary of Product Characteristics of Pradaxa® and idarucizumab.
- Pradaxa® is mainly eliminated by the kidneys; adequate diuresis must be maintained. Pradaxa® is dialyzable.
Please complete this section or ask your / your child’s doctor to do it.
Patient Information
________________________________
Name of the patient
_________________________________
Date of birth
_________________________________
Indication for anticoagulation
_________________________________
Dose of Pradaxa®
PATIENT ALERT CARD
Pradaxa® coated granules dabigatran etexilate
- This card should be with the caregiver or the patient at all times
- Make sure to use the latest version
[xxxx 20xx]
[Boehringer Ingelheim logo]
Dear Caregiver,
Your child’s doctor has initiated treatment with Pradaxa®. In order to use Pradaxa® safely, please consider the important information in the package leaflet.
As this patient alert card contains important information about your child’s treatment, this card should be with you or your child at all times to inform healthcare professionals about your child’s intake of Pradaxa®.
[Pradaxa logo]
Pradaxa® Information for Caregivers
About your child’s treatment
- Pradaxa® thins the blood. It is used to treat existing blood clots or to prevent the formation of dangerous blood clots.
- Follow your child’s doctor’s instructions for Pradaxa® use. Always administer the prescribed dose, never skip a dose or stop the use of Pradaxa® without talking to your child’s doctor.
- Inform your child’s doctor about all medicines your child is currently taking.
- Inform your child’s doctor about your child’s intake of Pradaxa® before any surgery/invasive procedure.
- Pradaxa® coated granules should be administered with soft food or apple juice according to the instructions for administration in the package leaflet. Do not use soft food containing milk products. Do not administer Pradaxa® coated granules via syringes or feeding tubes.
When to seek medical advice
- Taking Pradaxa® may increase the risk of bleeding. Speak to your child’s doctor immediately if your child experiences any signs and symptoms of bleeding such as: swelling, discomfort, unusual pain or headache, dizziness, paleness, weakness, unusual bruising, nosebleeds, bleeding of gums, unusually long bleeding cuts, abnormal menstrual flow or vaginal bleeding, blood in the urine which may be pink or brown, red/black stools, coughing up blood, vomiting blood or coffee ground like material.
- If your child falls or injures herself/himself, especially if she/he hits her/his head, urgently seek medical advice.
- Do not stop giving Pradaxa® without talking to your child’s doctor, if your child experiences heartburn, nausea, vomiting, stomach discomfort, bloating or upper abdominal pain.
Pradaxa® Information for Healthcare Professionals
- Pradaxa® is an oral anticoagulant (direct thrombin inhibitor).
- Pradaxa® may need to be stopped in advance of surgical or other invasive procedures.
- In case of major bleeding events, Pradaxa® must be stopped immediately.
- Pradaxa® is mainly eliminated by the kidneys; adequate diuresis must be maintained. Pradaxa® is dialyzable. See Summary of Product Characteristics.
Please complete this section or ask your child’s doctor to do it.
Patient Information
________________________________
Name of the patient
_________________________________
Date of birth
_________________________________
Indication for anticoagulation
_________________________________
Dose of Pradaxa®
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.